MAIA Biotechnology, Inc.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
(a) Recent sales of unregistered securities
On June 02, 2025, we issued 18,040 shares of our common stock with a value of $31,570 (based on the $1.75 closing price of our common stock on June 2, 2025) to FGMK, LLC, a greater than 5% holder of our common stock in consideration of accounting and tax assistance services. The issuance was exempt under Section 4(a)(2) of the Securities Act of 1933, as amended.
On June 18, 2025 we issued 17,083 shares of our common stock having a value of $30,751 (based on the $1.80 closing price of our common stock on June 18, 2025) to a service provider under a master services agreement in consideration of services rendered. The issuance was exempt under Section 4(a)(2) of the Securities Act of 1933, as amended.
(b) Purchases of equity securities by the issuer and affiliated purchasers.
None.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.